Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).
In an exclusive interview with CNBC-TV18's Ekta Batra and Reema Tendulkar, SS Marthi, Director of Transgene Biotek says, "The proposal is to raise USD 40 million via issuance of GDR. A part of this USD 40 million will be utilised for the present product line, which includes oncology drugs, active pharmaceutical ingredients (APIs), oral delivery platform of oral insulin, etc."
Going forward, the company is also looking at certain acquisitions, and, "the proceeds will be utilised for acquisitions as well," he adds.
The company is engaged in sales of medical diagnostic products and services.
Transgene Biote stock price
On November 26, 2015, at 12:27 hrs Transgene Biotek was quoting at Rs 2.35, up Rs 0.05, or 2.17 percent. The 52-week high of the share was Rs 4.84 and the 52-week low was Rs 1.71.
The latest book value of the company is Rs 23.51 per share. At current value, the price-to-book value of the company was 0.10.
READ MORE ON Transgene Biotek, biotechnology company, global depositary receipt, Ekta Batra, Reema Tendulkar, SS Marthi
Set email alert for
ADS BY GOOGLE
video of the day
Nifty to fall below 7500 if Q3 disappoints; GST key: Kumar